Kent and Canterbury Hospital | Renal Research Delivery Team

Research site
Ethelbert Rd, Canterbury, Kent, England
Site insights

Top conditions

Lymphoma (13 trials)

Multiple Myeloma (10 trials)

Plasma Cell Cancer (10 trials)

Prostatic Cancer (9 trials)

Leukemia (7 trials)

Top treatments

doxorubicin hydrochloride
vincristine sulfate
mitoxantrone hydrochloride
vinblastine sulfate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


11 of 60
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Warm Autoimmune Hemolytic Anemia
Other: Placebo
Drug: Obexelimab

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple mye...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Prednisone

The Cardamon trial is a phase 2 trial using the standard chemotherapy drugs cyclophosphamide and dexamethasone in combination with a new drug called...

Active, not recruiting
Multiple Myeloma
Procedure: Autologous Stem Cell Transplant (ASCT)
Drug: Consolidation with 4 cycles of CarCyDex

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritone...

End Stage Renal Disease
Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Drug: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available t...

Polycythemia Vera
Drug: Ruxolitinib
Drug: Hydroxycarbamide

Trial Title:FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple MyelomaOverview...

Multiple Myeloma
Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
Drug: R2: Lenalidomide plus placebo maintenance

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and sp...

Active, not recruiting
Biological: rituximab
Other: No treatment

Trial sponsors

University College London (UCL) logo

University College London (UCL) (8 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems